Other Information
+Added: On August 4, 2020, we entered into the Sales Agreement with Jefferies, as our sales agent, pursuant to which we may sell, from time to time, through Jefferies, shares of our common stock having an aggregate offering price of up to $65.0 million (Shares).
+Added: We are not obligated to make any sales of Shares under the Sales Agreement, and all sales will be made pursuant to a shelf registration statement on Form S-3, which was declared effective by the SEC on April 2, 2018, and as supplemented by a prospectus supplement to be filed with the SEC on or about the date of this Quarterly Report on Form 10-Q.
+Added: Under the Sales Agreement, Shares may be sold by any method deemed to be an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act, and, as a result, prices may vary.
+Added: We have agreed to pay Jefferies a commission of up to 3% of the aggregate gross proceeds we receive from all sales of Shares under the Sales Agreement, and we have also provided Jefferies with customary indemnification rights.
+Added: We and Jefferies may each terminate the Sales Agreement at any time upon prior written notice.
+Added: The foregoing description of the Sales Agreement is qualified in its entirety by reference to the Sales Agreement, a copy of which is attached hereto as Exhibit 1.1 and incorporated herein by reference.
+Added: The opinion of our counsel regarding the validity of the Shares that will be issued pursuant to the Sales Agreement is filed with this Quarterly Report on Form 10-Q as Exhibit 5.1.
The exhibits listed on the accompanying index to exhibits are filed or incorporated by reference (as stated therein) as part of this Quarterly Report on Form 10-Q.
Description of Document
+Added: Open Market Sale Agreement SM , dated August 4, 2020, by and between Rigel Pharmaceuticals, Inc.
+Added: and Jefferies LLC.
Amended and Restated Certificate of Incorporation.
4 unchanged sentences
Warrant issued to HCP BTC, LLC for the purchase of shares of common stock.
−Removed: Executive Severance Plan as amended .
+Added: Opinion of Cooley LLP.
+Added: Rigel Pharmaceuticals, Inc.
+Added: 2018 Equity Incentive Plan, as amended.
+Added: Consent of Cooley LLP (included in Exhibit 5.1).
Certification required by Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.
1 unchanged sentence
Certification required by Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.
−Removed: XBRL Instance Document
−Removed: XBRL Taxonomy Extension Schema Document
−Removed: XBRL Taxonomy Extension Calculation Linkbase Document
−Removed: XBRL Taxonomy Extension Labels Linkbase Document
−Removed: XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: XBRL Taxonomy Extension Definition Linkbase Document
+Added: Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
+Added: Inline XBRL Taxonomy Extension Schema Document
+Added: Inline XBRL Taxonomy Extension Calculation Linkbase Document
+Added: Inline XBRL Taxonomy Extension Labels Linkbase Document
+Added: Inline XBRL Taxonomy Extension Presentation Linkbase Document
+Added: Inline XBRL Taxonomy Extension Definition Linkbase Document
+Added: Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
Filed herewith
Indicates a management contract or compensatory plan or arrangement.
−Removed: Filed as an exhibit to Rigel’s Current Report on Form 8-K (No.
+Added: * The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C.
+Added: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act.
+Added: (1) Filed as an exhibit to Rigel’s Current Report on Form 8-K (No.
000-29889) filed on May 29, 2012, and incorporated herein by reference.
−Removed: Filed as an exhibit to Rigel’s Current Report on Form 8-K (No.
+Added: (2) Filed as an exhibit to Rigel’s Current Report on Form 8-K (No.
000-29889) filed on May 18, 2018, and incorporated herein by reference.
−Removed: Filed as an exhibit to Rigel’s Current Report on Form 8-K (No.
+Added: (3) Filed as an exhibit to Rigel’s Current Report on Form 8-K (No.
000-29889) filed on February 2, 2007, and incorporated herein by reference.
−Removed: Filed as an exhibit to Rigel’s Registration Statement on Form S-1 (No.
−Removed: 333-45864), as amended, and incorporated herein by reference.
−Removed: Filed as an exhibit to Rigel’s Current Report on Form 8-K (No.
+Added: (4) Filed as an exhibit to Rigel’s Registration Statement on Form S-1 (No.
+Added: 333-45864), filed on September 15, 2000, as amended, and incorporated herein by reference.
+Added: (5) Filed as an exhibit to Rigel’s Current Report on Form 8-K (No.
000-29889) filed on June 24, 2003, and incorporated herein by reference.
−Removed: Filed as an exhibit to Rigel’s Quarterly Report on Form 10-Q (No.
+Added: (6) Filed as an exhibit to Rigel’s Quarterly Report on Form 10-Q (No.
000-29889) for the quarter ended March 31, 2009, and incorporated herein by reference.
3 unchanged sentences
(Principal Executive Officer)
+Added: August 4, 2020
Chief Financial Officer
(Principal Financial Officer)
+Added: August 4, 2020
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.